Femasys earnings release, May 8, 2026

Femasys Inc (FEMY) · Form 8-K, Item 2.02 · Filed · SEC filing

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

-- With fertility rates at historic lows,

Femasys advances access to early infertility care through

FemaSeed®

Complete, enabling OB/GYNs to treat patients within their own practices --

ATLANTA, May 8, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announces its financial results for the quarter ended March 31, 2026 and provides a corporate update.

Corporate Highlights from 1Q 2026 to date

“During the first quarter of 2026 and into the second quarter of 2026, we delivered meaningful clinical, regulatory and commercial progress across our FemBloc and FemaSeed platforms,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “We are accelerating commercialization of FemaSeed with the introduction of the FemSperm® product family, enabling OB/GYNs to deliver integrated, in-office fertility care. Concurrently, we advanced FemBloc with initiation of patient enrollment in the FINALE pivotal clinical trial, a key step toward U.S. FDA approval. We believe our current cash resources are sufficient to fund operations into the third quarter of 2026. We remain focused on scaling a broad portfolio of innovative women’s health solutions globally, addressing critical unmet needs with safe, technologically advanced products.”

Financial Results for Quarter Ended March 31, 2026

For more information, please refer to the Company’s Form 10-Q filed May 8, 2026, which can be accessed on the

SEC website.

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

(continued)

FEMASYS INC.

Condensed Balance Sheets

(unaudited)

FEMASYS INC.

Condensed Statements of Comprehensive Income (Loss)

(unaudited)

About Femasys

Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed®

Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm®, a CLIA waived sperm preparation and analysis product line; and

FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rate of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.¹

FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select

European countries. Alongside FemBloc, the FemChec® diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.²

For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is ongoing.

Learn more at www.femasys.com, or follow us on

X,

Facebook and

LinkedIn.

References¹

Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal

Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count.

J Gynecol Reprod Med, 8(2), 01-12. doi:

10.33140/JGRM.08.02.08.²

Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent

Contraception for Occlusion of the Fallopian Tubes.

J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Financial statements

Income Statement

Three Months Ended March 31, — (unaudited)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Sales424,889341,264
Cost of sales (excluding depreciation expense)158,606117,266
Operating expenses:Research and development1,309,4012,968,472
Operating expenses:Sales and marketing1,315,755908,567
Operating expenses:General and administrative1,782,3901,722,713
Operating expenses:Depreciation and amortization82,27084,853
Operating expenses:Total operating expenses4,489,8165,684,605
Operating expenses:Loss from operations-4,223,533-5,460,607
Other income (expense):Interest income49,82719,029
Other income (expense):Change in fair value of conversion option liability1,513,413
Other income (expense):Change in fair value of warrants liabilities3,683,000
Other income (expense):Interest expense-176,607-459,449
Other income (expense):Total other income (expense), net5,069,633-440,420
Other income (expense):Income (loss) before income taxes846,100-5,901,027
Other income (expense):Income tax benefit-4,188
Other income (expense):Net income (loss)846,100-5,896,839
Other income (expense):Net income (loss) attributable to common stockholders328,646-5,896,839
Earnings (losses) per share:Basic0-0.23
Earnings (losses) per share:Diluted0-0.23
Weighted-average common shares outstanding:Basic66,645,59125,149,236
Weighted-average common shares outstanding:Diluted78,095,63325,149,236

Balance Sheet

March 31, 2026 — (unaudited)

March 31, 2026December 31, 2025
Current assets:Cash and cash equivalents5,386,0419,266,353
Current assets:Accounts receivable, net172,264616,600
Current assets:Inventory6,105,2675,740,249
Current assets:Prepaid and other current assets679,917833,133
Current assets:Total current assets12,343,48916,456,335
Property and equipment, at cost:Leasehold improvements1,238,8861,238,886
Property and equipment, at cost:Office equipment80,94178,155
Property and equipment, at cost:Furniture and fixtures421,798417,876
Property and equipment, at cost:Machinery and equipment3,095,6333,065,713
Property and equipment, at cost:Construction in progress955,271897,885
Property and equipment, at cost:5,792,5295,698,515
Property and equipment, at cost:Less accumulated depreciation-3,868,518-3,802,940
Property and equipment, at cost:Net property and equipment1,924,0111,895,575
Long-term assets:Lease right-of-use assets, net1,178,9411,297,121
Long-term assets:Intangible assets, net of accumulated amortization124,252134,914
Long-term assets:Other long-term assets924,552940,232
Long-term assets:Total long-term assets2,227,7452,372,267
Long-term assets:Total assets16,495,24520,724,177

Balance Sheet

Liabilities and Stockholders’ Equity — (unaudited)

March 31, 2026December 31, 2025
Current liabilities:Accounts payable1,597,5911,830,124
Current liabilities:Accrued expenses1,024,7061,265,773
Current liabilities:Clinical holdback – current portion52,57252,644
Current liabilities:Operating lease liabilities – current portion480,286487,624
Current liabilities:Total current liabilities3,155,1553,636,165
Long-term liabilities:Clinical holdback – long-term portion54,48752,370
Long-term liabilities:Convertible notes payable, net3,335,1763,178,864
Long-term liabilities:Conversion option liability488,0002,014,000
Long-term liabilities:Warrants liabilities1,260,0004,943,000
Long-term liabilities:Operating lease liabilities – long-term portion912,5341,030,476
Long-term liabilities:Total long-term liabilities6,050,19711,218,710
Long-term liabilities:Total liabilities9,205,35214,854,875
Stockholders’ equity:Common stock, $0.001 par, 200,000,000 authorized, 60,507,909 shares issued and 60,390,686 outstanding as of March 31, 2026; and 59,720,010 shares issued and 59,602,787 outstanding as of December 31, 202560,50859,720
Stockholders’ equity:Treasury stock, 117,223 common shares-60,000-60,000
Stockholders’ equity:Warrants5,246,1505,246,150
Stockholders’ equity:Additional paid-in capital147,023,279146,449,576
Stockholders’ equity:Accumulated deficit-144,980,044-145,826,144
Stockholders’ equity:Total stockholders’ equity7,289,8935,869,302
Stockholders’ equity:Total liabilities and stockholders’ equity16,495,24520,724,177
Full release

Forward-Looking Statements

This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; our ability to develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical... (truncated) products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and other reports as filed with the SEC.

Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

# # #

Contacts:

IR@femasys.com

Media@femasys.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Femasys earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.